ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Nervous System Diseases
Neurocognitive Disorders

Alzheimer's Disease trials near Berlin, BE, DEU:

Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PRImus-AD)

Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick toget ...

Enrolling
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease, Early Onset
Drug: Placebo
Drug: PRI-002

Phase 2

PRInnovation

Berlin, Germany and 38 other locations

progression of AD, as compared to no stimulation (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated Alzheimer's...

Active, not recruiting
Alzheimer Disease
Device: DBS-f On
Device: DBS Off
Functional Neuromodulation

Berlin, Germany and 20 other locations

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elder...

Active, not recruiting
Alzheimer's Disease (AD)
Drug: Placebo for ABBV-552
Drug: ABBV-552

Phase 2

AbbVie
AbbVie

Berlin, Germany and 63 other locations

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Other: Placebo
Biological: Bepranemab

Phase 2

UCB
UCB

Berlin, Germany and 101 other locations

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

Berlin, Germany and 168 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Berlin, Germany and 246 other locations

administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...

Enrolling
Alzheimer Disease
Drug: ACU193
Drug: Placebo

Phase 2, Phase 3

Acumen Pharmaceuticals

Berlin, Germany and 124 other locations

A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: AL002

Phase 2

Alector

Berlin, Germany and 91 other locations

The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarke...

Enrolling
Alzheimer Disease
Neurodegenerative Diseases
Drug: XPro1595
Drug: Placebo

Phase 2

INmune Bio

Berlin, Germany and 18 other locations

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or...

Enrolling
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Dementia
Drug: BIIB080-matching placebo
Drug: BIIB080

Phase 2

Biogen
Biogen

Berlin, Germany and 136 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems